Retatrutide 1kits (10Vials)

Retatrutide – Detailed Introduction & Benefits Retatrutide (LY3437943) is an investigational once‑weekly triple hormone receptor agonist developed by Eli Lilly. It is a 39‑amino‑acid synthetic peptide engineered to simultaneously activate three key metabolic receptors: GLP‑1, GIP, and glucagon (GCG) . This “triple agonist” design builds on dual agonists like tirzepatide (Mounjaro/Zepbound) by adding glucagon activation for stronger weight loss and metabolic benefits. It is administered via subcutaneous injection and is currently in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions. Core Mechanism of Action Retatrutide’s power comes from balancing three complementary pathways: GLP‑1 (Glucagon‑Like Peptide‑1) Boosts glucose‑dependent insulin secretion (lowers blood sugar only when high). Suppresses glucagon (prevents over‑production of sugar). Slows gastric emptying → longer fullness, reduced food intake. Acts on the brain to cut appetite and cravings . GIP (Glucose‑Dependent Insulinotropic Polypeptide) Amplifies insulin release, especially at normal/low glucose. Enhances fat breakdown (lipolysis) and improves fat distribution. Potentiates GLP‑1’s satiety effect for greater appetite control . Glucagon (GCG) Receptor (Unique to Retatrutide) Boosts energy expenditure (burns more calories at rest). Stimulates liver fat oxidation → targets belly and liver fat. Reduces liver fat buildup (improves NAFLD/MASH). Balanced by GLP‑1/GIP so it does not raise blood sugar . Net effect: Less hunger + more fat burn + better sugar control → unprecedented weight loss and metabolic improvement. Key Benefits (Proven in Clinical Trials) 1. Powerful & Sustained Weight Loss Phase 2 (48 weeks): Up to 24.2% body weight loss (average ~20–24%) in obese adults without diabetes. Phase 3 (TRIUMPH‑4): Average 71.2 lbs (32.3 kg) weight loss at 12 mg; 28.7% weight loss in some cohorts. More effective than tirzepatide (~22.5% max) and semaglutide (~15–17%). Targets visceral (belly) fat and liver fat first. 2. Superior Glycemic Control (Type 2 Diabetes) Reduces HbA1c by up to 2.16% (36 weeks) – better than dulaglutide. Lowers fasting and post‑meal blood sugar; improves insulin sensitivity. Benefits prediabetes and metabolic syndrome. 3. Liver Health & Fatty Liver Improvement Cuts liver triglycerides and ALT (liver enzyme) levels. Reduces hepatic steatosis (fatty liver) and may help MASH/NAFLD. 4. Metabolic & Cardiovascular Protection Lowers waist circumference, BMI, triglycerides, and LDL (“bad” cholesterol) . May reduce blood pressure and cardiovascular risk (under study). 5. Joint & Mobility Support Phase 3: Significant relief from knee osteoarthritis pain and improved function (linked to weight loss and reduced inflammation). 6. Safety & Tolerability Once‑weekly dosing improves adherence. Most common side effects: mild‑to‑moderate GI symptoms (nausea, diarrhea, constipation) – similar to other GLP‑1s. Low discontinuation rate (~12–18% at 9–12 mg). Difference vs. Tirzepatide (Dual Agonist) 表格 Feature Retatrutide (Triple) Tirzepatide (Dual) Receptors GLP‑1 + GIP + Glucagon GLP‑1 + GIP Max Weight Loss ~24–28% ~22.5% Liver Fat Targeting Stronger (glucagon) Moderate Energy Expenditure Increased Minimal Status & Usage Notes Not yet FDA‑approved (as of May 2026); Phase 3 trials ongoing for obesity, T2D, sleep apnea, and osteoarthritis Eli Lilly and Company . Investigational use only – available via clinical trials Eli Lilly and Company . Doses tested: 4 mg (maintenance), 9 mg, 12 mg once weekly.